The eventual progression of BRCA1/2-mutated breast or ovarian cancer, even after treatment with PARP inhibitors, has limited the success of this therapy in the clinic, emphasizing the need to identify mechanisms of this acquired resistance. The gene discussed is BRCA1; the disease is ovarian cancer.